Tr-KIT Downstream Regulation by YY1 and NFYA Transcription Factors Knockdown in Prostate Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Prostate cancer (PCa) is a significant health concern for men.
• Imatinib targets c-KIT but not tr-KIT, a truncated form over-expressed in PCa and linked to cancer progression.
• There is a need to enhance Imatinib's efficacy against PCa.

Purpose of the Study:

• To investigate if inhibiting tr-KIT specific transcription factors can enhance Imatinib's anti-proliferative effects on PCa cells.
• To identify key transcription factors regulating tr-KIT expression.

Main Methods:

• Gene expression analysis and cell viability assays were conducted on LNCaP prostate cancer cells.
• The study focused on inhibiting transcription factors YY1 and NFYA, known to control tr-KIT expression.
• Changes in gene expression for c-KIT, FYN, PLCγ1, and SAM68 were analyzed.

Main Results:

• YY1 and NFYA were confirmed as tr-KIT-specific transcription factors.
• Knockdown of YY1 and NFYA significantly increased the effectiveness of Imatinib mesylate treatment.
• SAM68 gene expression decreased following NFYA and YY1 knockdown, indicating potential novel pathway involvement.

Conclusions:

• tr-KIT represents a promising pharmacological target for prostate cancer treatment.
• Inhibiting transcription factors YY1 and NFYA can potentiate Imatinib's therapeutic efficacy.
• SAM68 is identified as a key protein affected by these interventions, warranting further investigation.